866-997-4948(US-Canada Toll Free)

Squamous Cell Carcinoma Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Apr 2013

Category :

Oncology

No. of Pages : 213 Pages


Global Markets Directs, \'Squamous Cell Carcinoma Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Squamous Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Squamous Cell Carcinoma. 

Squamous Cell Carcinoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Squamous Cell Carcinoma.
  • A review of the Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Squamous Cell Carcinoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Squamous Cell Carcinoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Squamous Cell Carcinoma Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Squamous Cell Carcinoma 9
Squamous Cell Carcinoma Therapeutics under Development by Companies 11
Squamous Cell Carcinoma Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Squamous Cell Carcinoma Therapeutics – Products under Development by Companies 21
Squamous Cell Carcinoma Therapeutics – Products under Investigation by Universities/Institutes 24
Companies Involved in Squamous Cell Carcinoma Therapeutics Development 26
Boehringer Ingelheim GmbH 26
F. Hoffmann-La Roche Ltd. 27
Shionogi & Co., Ltd. 28
Amgen Inc. 29
Eli Lilly and Company 30
GlaxoSmithKline plc 31
Genentech, Inc. 32
Millennium Pharmaceuticals, Inc. 33
Eisai Co., Ltd. 34
Takara Holdings Inc. 35
Idera Pharmaceuticals, Inc. 36
NexMed, Inc. 37
Clinuvel Pharmaceuticals Limited 38
Oncolytics Biotech Inc. 39
Cancer Research Technology Limited 40
Oryzon 41
Merrimack Pharmaceuticals, Inc. 42
Jennerex Biotherapeutics, Inc. 43
Omeros Corporation 44
Cellceutix Corporation 45
Cannabis Science, Inc. 46
IRX Therapeutics, Inc. 47
GENEXTRA S.p.A. 48
Laboratorio Elea S.A.C.I.F. and A 49
Biotech Pharmaceuticals Co., Ltd. 50
Squamous Cell Carcinoma – Therapeutics Assessment 51
Assessment by Monotherapy Products 51
Assessment by Combination Products 52
Assessment by Route of Administration 53
Assessment by Molecule Type 55
Drug Profiles 57
IMO-2055 - Drug Profile 57
alisertib - Drug Profile 59
trametinib - Drug Profile 61
golvatinib - Drug Profile 64
pemetrexed disodium - Drug Profile 66
litronesib - Drug Profile 72
pexastimogene devacirepvec - Drug Profile 74
Reolysin - Drug Profile 76
irinotecan hydrochloride nanoliposomal - Drug Profile 80
afamelanotide - Drug Profile 82
panitumumab - Drug Profile 84
Kevetrin - Drug Profile 87
IRX-2 - Drug Profile 90
HF-10 - Drug Profile 92
temsirolimus + [cetuximab] + [cisplatin]  - Drug Profile 93
everolimus + [paclitaxel] + [carboplatin] - Drug Profile 95
erlotinib hydrochloride + [cisplatin] + [docetaxel] - Drug Profile 97
bevacizumab + [cisplatin] + [docetaxel] + [fluorouracil] - Drug Profile 99
hydroxyurea + [cisplatin] + [docetaxel] + [fluorouracil] - Drug Profile 100
panitumumab + [cisplatin] + Radiation Therapy - Drug Profile 101
panitumumab + [cisplatin] + [fluorouracil] - Drug Profile 103
silicon phthalocyanine  - Drug Profile 105
ganitumab + [carboplatin] + [paclitaxel] - Drug Profile 107
Reolysin + [carboplatin] + [paclitaxel] - Drug Profile 109
afatinib - Drug Profile 112
imgatuzumab - Drug Profile 114
nimotuzumab + [cisplatin] + [fluorouracil] - Drug Profile 116
cetuximab + [fluorouracil] + [cisplatin] + Radiation Therapy - Drug Profile 118
nimotuzumab + [fluorouracil] + [irinotecan hydrochloride] + leucovorin - Drug Profile 119
BPM-31510 - Drug Profile 120
erlotinib hydrochloride + [cisplatin] + Radiation Therapy - Drug Profile 122
LY-2606368 - Drug Profile 124
nedaplatin + [docetaxel] - Drug Profile 125
nedaplatin + [docetaxel] - Drug Profile 126
talminogene laherparepvec + [cisplatin] + Radiation Therapy - Drug Profile 127
nedaplatin + [docetaxel] - Drug Profile 128
panitumumab + [cisplatin] + [docetaxel] - Drug Profile 129
RG-7597 - Drug Profile 130
erlotinib hydrochloride + [cisplatin] - Drug Profile 132
bevacizumab + [cisplatin] + Radiation Therapy - Drug Profile 134
MLN8237 + Cetuximab + Radiation - Drug Profile 135
bevacizumab + [fluorouracil] + [leucovorin calcium] + [oxaliplatin] - Drug Profile 137
S-488410 - Drug Profile 138
CIGB-300 - Drug Profile 139
everolimus + [carboplatin] + [cetuximab] - Drug Profile 140
golvatinib + [cetuximab] - Drug Profile 142
nimotuzumab + [cisplatin] - Drug Profile 144
nintedanib + [cisplatin] + [gemcitabine hydrochloride]  - Drug Profile 146
GPR87 Antagonist - Drug Profile 148
paclitaxel - Drug Profile 149
fluorouracil + [cisplatin] + [docetaxel] - Drug Profile 150
GPR39 Antagonist - Drug Profile 151
BXQ-350 - Drug Profile 152
Boanmycin Hydrochloride + [docetaxel] - Drug Profile 154
CS-TATI-1 Research Program - Drug Profile 155
mAb For Squamous Cell Cancer - Drug Profile 157
interferon alfa-2b + interferon gamma-1b - Drug Profile 158
interleukin-15 - Drug Profile 159
ABT-414 - Drug Profile 160
DAC-0060 - Drug Profile 161
CS-S/BCC-1 - Drug Profile 162
Antibody Against FERM Domain-Containing Protein 4A - Drug Profile 163
Squamous Cell Carcinoma Therapeutics – Drug Profile Updates 164
Squamous Cell Carcinoma Therapeutics – Discontinued Products 194
Squamous Cell Carcinoma Therapeutics - Dormant Products 195
Squamous Cell Carcinoma – Product Development Milestones 198
Featured News & Press Releases 198

Appendix 207
Methodology 207
Coverage 207
Secondary Research 207
Primary Research 207
Expert Panel Validation 207
Contact Us 208
Disclaimer 208

List of Table


Number of Products Under Development for Squamous Cell Carcinoma, H1 2013 14
Products under Development for Squamous Cell Carcinoma Comparative Analysis, H1 2013 15
Number of Products under Development by Companies, H1 2013 17
Number of Products under Development by Companies, H1 2013 (Contd..1) 18
Number of Products under Investigation by Universities/Institutes, H1 2013 20
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 21
Comparative Analysis by Late Stage Development, H1 2013 22
Comparative Analysis by Mid Clinical Stage Development, H1 2013 23
Comparative Analysis by Early Clinical Stage Development, H1 2013 24
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 25
Products under Development by Companies, H1 2013 26
Products under Development by Companies, H1 2013 (Contd..1) 27
Products under Development by Companies, H1 2013 (Contd..2) 28
Products under Investigation by Universities/Institutes, H1 2013 29
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 30
Boehringer Ingelheim GmbH, H1 2013 31
F. Hoffmann-La Roche Ltd., H1 2013 32
Shionogi & Co., Ltd., H1 2013 33
Amgen Inc., H1 2013 34
Eli Lilly and Company, H1 2013 35
GlaxoSmithKline plc, H1 2013 36
Genentech, Inc., H1 2013 37
Takara Holdings Inc., H1 2013 40
Idera Pharmaceuticals, Inc., H1 2013 41
NexMed, Inc., H1 2013 42
Clinuvel Pharmaceuticals Limited, H1 2013 43
Oncolytics Biotech Inc., H1 2013 44
Cancer Research Technology Limited, H1 2013 45
Oryzon, H1 2013 46
Merrimack Pharmaceuticals, Inc., H1 2013 47
Jennerex Biotherapeutics, Inc., H1 2013 48
Omeros Corporation, H1 2013 49
Cellceutix Corporation, H1 2013 50
Cannabis Science, Inc., H1 2013 51
IRX Therapeutics, Inc., H1 2013 52
GENEXTRA S.p.A., H1 2013 53
Laboratorio Elea S.A.C.I.F. and A, H1 2013 54
Biotech Pharmaceuticals Co., Ltd., H1 2013 55
Assessment by Monotherapy Products, H1 2013 56
Assessment by Combination Products, H1 2013 57
Assessment by Stage and Route of Administration, H1 2013 59
Assessment by Stage and Molecule Type, H1 2013 61
Squamous Cell Carcinoma Therapeutics Drug Profile Updates 169
Squamous Cell Carcinoma Therapeutics Discontinued Products 199
Squamous Cell Carcinoma Therapeutics Dormant Products 200
Squamous Cell Carcinoma Therapeutics Dormant Products (Contd..1) 201
Squamous Cell Carcinoma Therapeutics Dormant Products (Contd..2) 202

List of Chart


Number of Products under Development for Squamous Cell Carcinoma, H1 2013 14
Products under Development for Squamous Cell Carcinoma Comparative Analysis, H1 2013 15
Products under Development by Companies, H1 2013 16
Products under Investigation by Universities/Institutes, H1 2013 19
Late Stage Products, H1 2013 22
Mid Clinical Stage Products, H1 2013 23
Early Clinical Stage Products, H1 2013 24
Discovery and Pre-Clinical Stage Products, H1 2013 25
Assessment by Monotherapy Products, H1 2013 56
Assessment by Combination Products, H1 2013 57
Assessment by Route of Administration, H1 2013 58
Assessment by Stage and Route of Administration, H1 2013 59
Assessment by Molecule Type, H1 2013 60
Assessment by Stage and Molecule Type, H1 2013 61

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *